Environmental exposures in 513 patients of hypersensitivity pneumonitis: Prospective ILD India registry

Sheetu Singh (Jaipur, India), Sheetu Singh, Bridget Collins, Bharat Bhushen Sharma, Jyotsana M. Joshi, Deepak Talwar, Sandeep Katiyar, Nishtha Singh, Lawrence Ho, Jai Kumar Samaria, Parthasarthi Bhattacharya, Rakesh Gupta, Sudhir Chaudhari, Tejraj Singh, Vijay Moond, Sudhakar Pipavath, Jitesh Ahuja, Ravindran Chetambath, Aloke G. Ghoshal, Nirmal Kumar Jain, H.J. Gayathri Joshy, Surya Kant, Parvaiz Koul, Raja Dhar, Rajesh Swarnkar, Surendra K. Sharma, Dhrubajyoti Roy, Kripesh R. Sarmah, Bhavin Jankharia, Rodney A. Schmidt, Virendra Singh, Ganesh Raghu

Source: International Congress 2016 – Orphan diseases I
Session: Orphan diseases I
Session type: Thematic Poster
Number: 3882
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Sheetu Singh (Jaipur, India), Sheetu Singh, Bridget Collins, Bharat Bhushen Sharma, Jyotsana M. Joshi, Deepak Talwar, Sandeep Katiyar, Nishtha Singh, Lawrence Ho, Jai Kumar Samaria, Parthasarthi Bhattacharya, Rakesh Gupta, Sudhir Chaudhari, Tejraj Singh, Vijay Moond, Sudhakar Pipavath, Jitesh Ahuja, Ravindran Chetambath, Aloke G. Ghoshal, Nirmal Kumar Jain, H.J. Gayathri Joshy, Surya Kant, Parvaiz Koul, Raja Dhar, Rajesh Swarnkar, Surendra K. Sharma, Dhrubajyoti Roy, Kripesh R. Sarmah, Bhavin Jankharia, Rodney A. Schmidt, Virendra Singh, Ganesh Raghu. Environmental exposures in 513 patients of hypersensitivity pneumonitis: Prospective ILD India registry. Eur Respir J 2016; 48: Suppl. 60, 3882

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan
Source: ERJ Open Res, 6 (2) 00184-2019; 10.1183/23120541.00184-2019
Year: 2020



Profiling of hypersensitivity pneumonitis diagnosed at a UK specialist service for ILD and occupational lung diseases
Source: International Congress 2018 – Occupational and environmental lung diseases: asthma and the airways
Year: 2018



Prevalence of occupational and environmental exposures in Australian patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Occupational asthma, abestosis and silicosis
Year: 2014

Risk factors for idiopathic pulmonary fibrosis in Southern Europe: A case-control study
Source: Annual Congress 2013 –Occupational respiratory diseases: asthma, silicosis and asbestosis
Year: 2013

Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry
Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis
Year: 2021



Clinical study of pediatric interstitial lung diseases in China
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013


PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting
Source: International Congress 2014 – ILDs 6
Year: 2014


Emphysematous changes in chronic hypersensitivity pneumonitis: A retrospective analysis of 12 patients
Source: International Congress 2016 – Orphan diseases II
Year: 2016

Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone
Source: International Congress 2016 – Orphan diseases II
Year: 2016

Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome
Source: International Congress 2014 – ILDs 2
Year: 2014

Treatment dilemmas in sarcoidosis - a retrospective cohort study
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013

Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe.
Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis
Year: 2021



Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort
Source: International Congress 2016 – The best is yet to come in terms of lung function
Year: 2016



Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry
Source: Virtual Congress 2020 – Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases
Year: 2020




Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial
Source: International Congress 2014 – ILDs 3
Year: 2014


Incidence and prevalence of Systemic Sclerosis-associated Interstitial Lung Disease in a multicenter prospective cohort study.
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020


A case of welder's lung with a differential diagnosis of hypersensitivity pneumonitis
Source: International Congress 2014 – Occupational respiratory diseases
Year: 2014


A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2014 – IPF and surroundings
Year: 2014

Criteria for PF-ILD in a cohort of patients with chronic hypersensitivity pneumonitis
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020


Interstitial lung diseases in children: The French national cohort study
Source: Annual Congress 2011 - Rare diffuse lung diseases
Year: 2011